Commercial Success of Lead Product: The Company's financial performance heavily depends on the successful commercialization, market adoption, and sales of Vyjuvek (beremagene geperpavec) for Dystrophic Epidermolysis Bullosa (DEB) in the United States, as well as its potential approval and commercialization in other regions.

Future Clinical Development Pipeline: The success of Krystal Biotech relies on the successful advancement, conduct, and completion of clinical trials for its pipeline candidates, such as KB105 for Atopic Dermatitis or KB104 for Chronic Wounds, which are subject to inherent risks of failure, delays, or unexpected adverse events.

Regulatory Approval for New Products/Indications: Achieving additional regulatory approvals for Vyjuvek in new indications or for other pipeline products is uncertain and subject to the discretion of regulatory agencies, which may require extensive data, impose stringent conditions, or ultimately deny approval.